Keyword: PTC Therapeutics
JPMorgan discovered concerns about the efficacy of Novartis' Zolgensma that could make it difficult for the SMA gene therapy to meet expectations.
PTC Therapeutics is aiming for two key drug launches and amping up its gene therapy pipeline, and it needed more capacity to make it all happen.
Duchenne muscular dystrophy drug Emflaza sparked controversy under its previous owner, but its new owner, PTC Therapeutics, is forging ahead.
Sarepta Therapeutics’ DMD therapy Exondys has already been knocked for its skimpy clinical data. Now a price watchdog says it’s also too expensive.
PTC is facing questions about an issue that has dogged the company since it bought DMD drug Emflaza from Marathon last March: the drug’s rising price.
Rep. Elijah Cummings, D-Md., is urging President Trump to press for lower prices on Biogen's multiple sclerosis drug Zinbryta.
PTC says it'll charge $35,000 for Emflaza, the Duchenne drug it bought from Marathon in March, amid a brouhaha over its $89,000 list price. Is the new sticker low enough?
After a big slowdown in 2016, FDA new drug approvals got off to a hot start in 2017.
PTC Therapeutics faces an uphill battle to extract brand-level pricing and sales with its new DMD drug Emflaza according to a new policy report.
When PTC agreed to buy Marathon's Emflaza last week, it inherited congressional scrutiny on the drug's price, originally set at a much-lambasted $89,000.